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Abstract
Objective To evaluate the association of volume limited and pressure
limited (lung protective) mechanical ventilation with two year survival in
patients with acute lung injury.
Design Prospective cohort study.
Setting 13 intensive care units at four hospitals in Baltimore, Maryland,
USA.
Participants 485 consecutive mechanically ventilated patients with
acute lung injury.
Main outcome measure Two year survival after onset of acute lung
injury.
Results 485 patients contributed data for 6240 eligible ventilator settings,
as measured twice daily (median of eight eligible ventilator settings per
patient; 41% of which adhered to lung protective ventilation). Of these
patients, 311 (64%) died within two years. After adjusting for the total
duration of ventilation and other relevant covariates, each additional
ventilator setting adherent to lung protective ventilation was associated
with a 3% decrease in the risk of mortality over two years (hazard ratio
0.97, 95% confidence interval 0.95 to 0.99, P=0.002). Compared with
no adherence, the estimated absolute risk reduction in two year mortality
for a prototypical patient with 50% adherence to lung protective ventilation
was 4.0% (0.8% to 7.2%, P=0.012) and with 100% adherence was 7.8%
(1.6% to 14.0%, P=0.011).
Conclusions Lung protective mechanical ventilation was associated
with a substantial long term survival benefit for patients with acute lung
injury. Greater use of lung protective ventilation in routine clinical practice
could reduce long term mortality in patients with acute lung injury.
Trial registration Clinicaltrials.gov NCT00300248.
Introduction
Survivors of severe critical illness, such as acute lung injury,
and its more severe subset, acute respiratory distress syndrome
(ARDS), commonly experience increased mortality and
morbidity in the months and years after hospital discharge.
1-3
Comparedwithagematchedandsexmatchedcontrols,patients
dischargedfromintensivecarearetwotofivetimesmorelikely
to die during three to 15 years’ follow-up.
3 Few interventions
have been evaluated for improving this increased long term
mortality.
4
Randomised trials and meta-analyses have shown that use of
volume limited and pressure limited mechanical ventilation
(lung protective ventilation) in patients with acute lung injury
substantially decreases short term mortality.
5-9 A randomised
trial of lung protective ventilation carried out by the ARDS
Network
8 found an 8.8% absolute reduction in short term
mortality. This trial evaluated a ventilator tidal volume of 6
mL/kg predicted body weight (calculated on the basis of a
patient’ssexandheight
8)andaplateaupressure(airwaypressure
measured after a 0.5 second end inspiratory pause) of ≤30 cm
of water compared with a tidal volume of 12 mL/kg predicted
body weight and a plateau pressure of ≤50 cm of water.
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Research
RESEARCHUnderstanding the effect of lung protective ventilation on long
term survival is important,
4 5 especially since critical care
interventions with a mortality benefit at hospital discharge may
not have a sustained benefit thereafter.
10 Lung protective
ventilation may have long term benefits owing to its reductions
in inflammation, ventilator induced lung injury, and duration
of non-pulmonary organ failure in the setting of the intensive
care unit.
8 11
We evaluated the association of lung protective ventilation and
averageventilatortidalvolumewithtwoyearsurvivalinpatients
with acute lung injury. We carried out this evaluation using a
prospectivecohortstudydesigntounderstandtheepidemiology
and effects of lung protective ventilation as part of routine
medical care and to avoid the ethical issues associated with
randomly allocating patients to higher tidal volumes and
pressures as part of a randomised trial.
Methods
From 2004-7 we enrolled into a prospective cohort study 520
consecutive mechanically ventilated patients with acute lung
injury, diagnosed according to the American-European
Consensus criteria (box).
12 Patients were recruited from 13
medical, surgical, and trauma intensive care units at four
academic teaching hospitals in Baltimore, Maryland, United
States. Intensive care units that specialised in patients with
neurologicalconditions,andpatientswithacutelunginjurywith
primary neurological disease or head trauma were not eligible.
We excluded patients who had pre-existing comorbid illness
with a life expectancy of six or less months (for example,
metastatic cancer), pre-existing cognitive impairment or
communication/language barriers, no fixed address for
follow-up, been transferred from another hospital and had
pre-existing acute lung injury of more than 24 hours’ duration,
been mechanically ventilated for more than five days before
onset of acute lung injury, previous lung resection, and a
physician order for no escalation of care in the intensive care
unit(forexample,novasopressors)atonsetofacutelunginjury.
We obtained informed consent for prospective follow-up in
writing after patients regained decision making capacity (or
through proxies if patients remained incapable of decision
making).
13
Assessment of primary outcome: mortality
We prospectively evaluated patients at 3, 6, 12, and 24 months
after onset of acute lung injury. Mortality status and date of
death were obtained from family members and subsequently
verified using a commercial version of the social security death
master file
14 or other publicly accessible records of death. Any
patient for whom we could not determine mortality status was
censored at the last day known to be alive.
Assessment of primary exposure: lung
protective mechanical ventilation
After onset of acute lung injury, we recorded mechanical
ventilator settings twice daily at 6 am and 6 pm for the duration
ofthepatient’sventilationatthestudysitehospital.Aventilator
setting was defined as being “eligible” for lung protective
ventilation if mechanical ventilation was delivered through an
endotracheal or tracheostomy tube with a fraction of inspired
oxygen (FiO2) ≥0.50 or positive end expiratory pressure >5 cm
of water. We chose this definition of eligible because it
approximated the threshold at which the ARDS Network
ventilation protocol permitted trials of spontaneous breathing
in which tidal volume and plateau pressure were not specified
and controlled, and discontinuation of mechanical ventilation
could be evaluated.
Aventilatorsettingwasdefinedas“adherent”tolungprotective
ventilation if it was an eligible setting that met two criteria: tidal
volume ≤6.5 mL/kg predicted body weight (the threshold used
in the ARDS Network tidal volume trial to designate study site
adherencetothegoaltidalvolumeof6.0mL/kgpredictedbody
weight) and a plateau pressure of ≤30 cm of water (based on
documentation of respiratory therapy; in pressure regulated
modesofventilation,inwhichplateaupressureisnotmeasured,
we used peak pressure or the sum of positive end expiratory
pressure and the prescribed increment in inspiratory pressure).
We considered ventilator settings that used a mode of
mechanical ventilation for which tidal volume is not routinely
measured(thatis,highfrequencyoscillationorairwaypressure
releasemodes)tobenoteligibleforassessingadherencetolung
protectiveventilationbutwestillincludedtheminthestatistical
analysisusingthecumulativenumberofeachoftheseventilator
modes as time varying covariates. We excluded from analyses
those patients without at least one eligible ventilator setting
before death or discontinuation of mechanical ventilation
because adherence to lung protective ventilation is undefined
in this patient subset.
Assessment of baseline and time varying
covariates
Inthisstudywemeasuredcovariatespotentiallyassociatedwith
ventilator settings or mortality, based on previous literature (for
example,
15)andasystematicprocess.
16Weevaluated10baseline
variables: age, sex, body mass index category, comorbidity
(Charlson index
17), severity of illness within 24 hours of
admission to an intensive care unit (acute physiology and
chronic health evaluation II score),
18 primary risk factor for
acute lung injury, type of intensive care unit (medical versus
surgical), patient location before admission to intensive care
(for example, emergency department), year of enrolment to
study (first, second, or third), and study site identifier (1, 2, 3,
or 4). Throughout the duration of ventilation we obtained time
varying covariates from the medical record twice daily at 6 am
and 6 pm, when recorded: positive end expiratory pressure,
pressure of arterial oxygen (PaO2), FiO2, arterial pH, and actual
respiratory rate. From the data we calculated and included in
the model a twice daily measure of static compliance of the
respiratory system.
19 Additional time varying covariates were
measured once daily in the intensive care unit, including organ
dysfunction (sequential organ failure assessment score
20),
sedation and delirium status (Richmond agitation and sedation
scale,
21 and confusion assessment method for the intensive care
unit
22), dose of systemic corticosteroids and neuromuscular
blocking agents, and net fluid balance (total fluid input minus
total fluid output).
Statistical analysis
We used descriptive statistics to summarise the data and
compared these using Wilcoxon rank-sum and Fisher’s exact
tests,asappropriate.AKaplan-Meiercurvewasusedtodescribe
the survival experience over the two years of follow-up.
A multivariable Cox proportional hazards regression model
with time varying covariates was used to estimate the hazard
ratios of mortality as a function of lung protective ventilation
(the primary exposure variable) and all 27 covariates chosen a
priori based on clinical relevance. The primary exposure was
modelled as the time varying number of ventilator settings
adherent to lung protective ventilation, with adjustment for the
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RESEARCHAmerican-European Consensus Conference criteria for acute lung injury and acute respiratory distress syndrome
12
• Timing: acute onset
• Oxygenation: PaO2:FiO2 ≤300 mg Hg (acute lung injury) or ≤200 mg Hg (acute respiratory distress syndrome)
• Frontal chest radiography findings: bilateral infiltrates
• No clinical evidence of left atrial hypertension or pulmonary artery wedge pressure ≤18 mm Hg
total duration of mechanical ventilation. When a similar
magnitude of hazard ratios existed between categories we
collapsed the categorical variables to binary variables. We
examined Martingale residual plots to confirm appropriate
modelling of continuous covariates, with no departures from
linearity detected. Analysis of variance inflation factors
confirmed the absence of any important multicollinearity in the
full multivariable model. The Cox model allowed for separate
baseline hazard functions for mortality during stay in the
intensive care unit compared with after stay, as defined by a
timevaryingindicatorofdischargefromtheintensivecareunit.
We assessed the proportional hazard assumption for the full
modelusingatrendtestbasedontheSchoenfeldresiduals
23and
graphicaldisplaysofthecumulativeSchoenfeldresidualsversus
event times for each explanatory variable, indicating no
important violation of this assumption.
24
Toillustratetheeffectoflungprotectiveventilationonmortality,
we used the multivariable Cox model to predict the survival
function and cumulative risk of mortality at 1, 6, 12, 18, and 24
monthsafteronsetofacutelunginjuryforaprototypicalpatient
who survived for at least four days of eligible mechanical
ventilation and had median values for all continuous covariates
and mode values for all binary covariates.
Missing data
For days in the intensive care unit during which a sedation or
deliriumassessmentwasnotcompleted,wemadeaconservative
assumption that coma (Richmond agitation and sedation scale
score−4or−5)anddeliriumwerenotpresent.Formissingdata
on plateau pressure we used multiple imputation
25 (with five
datasets), as in previous research using ARDS Network data.
26
Asasecondaryanalysis,werepeatedallanalysesusingasubset
of the entire dataset excluding patients with complete missing
ventilator data required for measuring the primary exposure to
compare with results from the primary analysis using multiple
imputation for missing data.
Additional analyses
We carried out additional a priori analyses. To determine if the
findings were robust to the tidal volume and plateau pressure
thresholds that defined an adherent ventilator setting, we reran
the multivariable Cox model using different thresholds for
adherence both for tidal volume (≤6.0 to ≤9.0 mL/kg predicted
bodyweight)andforplateaupressure(≤25to≤45cmofwater).
In addition, we explored the association of mean tidal volume
(analysed as a time varying variable over the duration of
mechanicalventilation)withtwoyearsurvival,modellingmean
tidal volume as both a three level categorical exposure variable
(<6.5, 6.5-8.5, and >8.5 mL/kg predicted body weight) and a
continuous exposure variable. Using the same multivariable
regressionmodel,wealsoevaluatedwhethermeantidalvolume,
consideredasacontinuousexposurevariablewithoutaccounting
for plateau pressure, had a linear association with two year
survival. In this evaluation, we calculated the estimated change
in hazard of mortality across mean tidal volume between the
multivariableCoxmodelassumingalinearrelationwithsurvival
comparedwithassumingaflexible,non-linearrelationachieved
by adding a cubic spline (with three degrees of freedom) into
the model.
We also carried out a post hoc propensity score analysis
approach for non-binary treatments
27 to compare with the
primaryanalysis.Separatepropensityscoreswerecreatedusing
Poisson regression models for each of the number of eligible
ventilatorsettingsandthenumberofadherentventilatorsettings
using the previously described covariates for the multivariable
regression models. Data were stratified into nine strata based
on three levels of each propensity score, with a Cox model fit
within each stratum with further adjustment for a subset of the
relevant covariates. We calculated the overall propensity score
adjusted hazard ratio and associated variance as a weighted
average of the strata specific estimates.
We calculated that we would require a sample size of 520
patients to show a relative hazard of 0.70 for two year survival
comparingtwoequallysizedgroupsofpatients(thosereceiving
greater than compared with less than the median proportion of
eligible ventilation days using lung protective ventilation) with
an α of 0.05 and statistical power of more than 85%. Statistical
significance was defined as a two sided P<0.05. All analyses
were completed using R statistical software (version 2.11.1).
Results
Overall, 35 of 520 patients were excluded from analysis: 32
(6%) had no eligible ventilator settings and three (<1%) had
missing data on height required for calculating predicted body
weight and adherence to lung protective ventilation (fig 1⇓).
Thus data from 485 patients, with 6240 eligible ventilator
settings and 12 202 total ventilator settings, were available for
analysis. For the secondary analysis of complete data, 30 (6%)
of the 485 eligible patients were excluded owing to missing
ventilatorvariablesrequiredformeasuringtheprimaryexposure,
leaving 455 patients with 4938 eligible ventilator settings and
10 321 total ventilator settings.
Tables1⇓and2⇓presentthepatients’characteristics,ventilator
variables,andothercovariatesrelatedtotheintensivecareunit,
by adherence to lung protective ventilation and by two year
mortality status. Of 485 patients, 274 (57%) were male and the
median age (years) was 53 (interquartile range 42-63). Patients
were predominantly admitted to a medical (compared with
surgical) intensive care unit, with a median severity of illness
(acute physiology and chronic health evaluation II) score of 27
(interquartile range 20-33, table 1). The median number of
eligibleventilatorsettingsperpatientwas8(interquartilerange
3-15). The median duration (days) of mechanical ventilation
was 9 (interquartile range 5-17), stay in the intensive care unit
was 13 (8-22), and hospital stay was 21 (13-36).
Of 6240 eligible ventilator settings, 2548 (41%) were adherent
tolungprotectiveventilation,withnosignificanttemporaltrends
in adherence observed over the three year study period. Of the
485 patients, 417 (86%) received 50% or less and 68 (14%)
received more than 50% of their twice daily ventilator settings
adherent to lung protective ventilation. A total of 180 (37%)
patients never received lung protective ventilation during any
of their twice daily ventilator settings. Patients who were ever
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RESEARCH(versus never) exposed to lung protective ventilation were
younger, and a significantly greater proportion were male and
received neuromuscular blockers (table 1).
Overall,311(64%)ofthe485patientsdiedduringthetwoyears
after onset of acute lung injury. Mortality status at two years
was not available for 29 (6.0%) of the 485 patients, and these
patients were censored in the analysis. The mortality rate
increasedovertime,particularlyoverthefirstyearoffollow-up,
from 44% at 30 days to 52% at 90 days and 62% at one year
(fig2⇓).Thosewhowerealiveaftertwoyearsweresignificantly
younger with lower comorbidity, severity of illness, and organ
failure scores (table 1).
During the two year follow-up, survival was independently
associated with several covariates: younger age; lower
comorbidity,organfailurescores,cumulativefluidbalance,and
dayswithneuromuscularblockers;andagreaternumberofhigh
frequency oscillation or airway pressure release ventilator
settings (table 3⇓). After adjusting for the total duration of
mechanical ventilation and all other covariates, for each
additional adherent ventilator setting measured twice daily, the
risk of mortality over two years decreased by 3% (hazard ratio
0.97, 95% confidence interval 0.95 to 0.99, P=0.002). For a
prototypicalpatient,thisfindingequatestoanestimatedabsolute
risk reduction in two year mortality of 4.0% (95% confidence
interval 0.8% to 7.2%, P=0.012) for 50% ventilator adherence
and 7.8% (1.6% to 14.0%, P=0.011) for 100% adherence
comparedwitha49.7%baselinemortalityundertheassumption
of no adherence to lung protective ventilation (fig 3⇓).
The results of the primary analysis of 485 patients were robust
to varying both the tidal volume and the plateau pressure
thresholds used to define adherence to lung protective
ventilation. In addition, the primary results using multiple
imputation for missing data were similar when replicated in the
secondary analysis of 455 patients, which excluded those with
complete missing data for the primary exposure, with a hazard
ratioforeachadditionaladherentventilatorsettingof0.96(95%
confidence interval 0.94 to 0.99, P=0.001). Finally, results of
the post hoc propensity score analyses were consistent with
results from the primary analysis.
Comparedwithameantidalvolume<6.5mL/kgpredictedbody
weight, the adjusted hazard ratios for two year mortality for a
mean tidal volume of 6.5 to 8.5 mL/kg predicted body weight
was 1.59 (1.19 to 2.14, P=0.001) and for >8.5 mL/kg predicted
bodyweightwas1.97(1.23to3.16,P=0.004).Moreover,when
tidalvolumewasmodelledasacontinuousvariable,noevidence
supported a non-linear relation between two year survival and
mean tidal volume (fig 4⇓; P=0.182 for the non-linear terms of
a cubic spline model), with an adjusted hazard ratio of 1.18
(1.07 to 1.31, P=0.001), indicating an 18% relative increase in
mortality for each 1 mL/kg predicted body weight increase in
average tidal volume.
Discussion
Inthismultisite,prospectivecohortstudyofpatientswithacute
lung injury, adherence to lung protective ventilation was
associated with improved two year survival, with an absolute
reductioninmortalityofabout4%and8%when50%and100%
adherence, respectively, were compared with no adherence.
These findings were robust to differing thresholds of tidal
volume and plateau pressure used to define adherence to lung
protective ventilation. Moreover, average tidal volume showed
an independent linear relation with two year survival, with an
18% relative increase in the risk of mortality over two years for
each 1 mL/kg predicted body weight increase in average tidal
volumeoverthedurationofmechanicalventilation.Thus,within
the setting of routine clinical practice, use of lung protective
ventilationwasstronglyassociatedwithasubstantial,longterm
survival benefit for patients with acute lung injury.
Comparison with other studies
No existing studies of lung protective ventilation have been
designed to evaluate long term survival in patients.
6 The high
two year mortality observed in this study is consistent with
previous research showing increased long term mortality for
patients after discharge from an intensive care unit versus age
and sex matched population controls, and with the known risks
for long term mortality, including high comorbidity, organ
failure, and severity of illness,
3 28 29 which were observed in this
patient sample.
This observational study allowed evaluation of lung protective
ventilation within a setting of routine clinical practice in four
teaching hospitals. Only 41% of all eligible ventilator settings
were adherent to lung protective ventilation, and when twice
dailycollectedventilatorsettingswereevaluated37%ofpatients
never received lung protective ventilation. These results
represent an improvement from previous studies
30-32 and from
usual care practice before randomisation in the original ARDS
Network trial in which mean baseline tidal volume was 10
mL/kg predicted body weight.
8 There are many known reasons
for non-adherence to lung protective ventilation
31 33-35 and still
substantial room for improvement with use of this life saving
intervention.
6 36 37 Rigorous knowledge translation research,
aimedatimprovingtheimplementationofclinicalresearchinto
practice,isneededtomaximisethepublic’sreturnoninvestment
from clinical and preclinical research that established the short
term efficacy of lung protective ventilation.
37 These knowledge
translation efforts are especially important given the ageing
population and the higher incidence and mortality associated
with acute lung injury and mechanical ventilation with
increasing age.
38-40
In this study, the duration of neuromuscular blockade (but not
cumulative dose) was associated with an increased risk of
mortality over two years. These findings contrast with the 90
day survival benefit of early neuromuscular blockade in severe
acute respiratory distress syndrome from a recent randomised
trial.
41 This difference in findings is possibly due, in part, to
noticeably different use of these drugs in this study compared
with the randomised trial protocol.
This study also found a two year survival benefit with use of
high frequency oscillation and airway pressure release modes
of ventilation in selected patients, with adjusted hazard ratios
foreachadditionalhighfrequencyoscillationorairwaypressure
release ventilator setting (measured twice daily) of 0.93 (95%
confidence interval 0.88 to 0.97, P=0.002) and 0.98 (0.96 to
0.99, P=0.005), respectively. However, the study was not
specifically designed and analysed to evaluate these alternative
modes of ventilation, which have not been compared with
conventional lung protective ventilation in any large scale
randomised trial.
6 Hence the results for these alternative modes
of ventilation must be interpreted with caution.
Limitations of the study
This study has potential limitations. Firstly, as this study was
observationalwecannotprovecausationbetweenlungprotective
ventilationandincreasedtwoyearsurvivalsincebothmeasured
andunmeasuredcharacteristicsdifferedbetweenpatientgroups
receiving and not receiving lung protective ventilation. Given
the decrease in short term mortality established in previous
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RESEARCHstudies,
5-9 however, a randomised trial to evaluate the long term
effects of lung protective ventilation would not be ethical.
Causality is plausible given the known short term benefits of
lung protective ventilation
6-9 11 and the dose-response effect of
lungprotectiveventilationobservedinthisstudy.Secondly,the
plateau pressure required for determining adherence to lung
protective ventilation was not always recorded in the medical
record,occurringin21%oftheeligibleventilatorsettings,with
a median number of missing values across all 485 patients of 1
(interquartile range 0-3). This is not an uncommon finding in
routine clinical practice, with plateau pressure, peak end
expiratory pressure, or tidal volume missing in about 40% of
patients in both a population based observational study
42 and in
the ARDS Network trial before randomisation of the groups.
8
These missing data have the potential to bias results; however,
both the primary analysis with imputation of missing data and
a secondary complete case analysis showed similar results,
which provide some reassurance. Greater efforts to routinely
measureandrecordplateaupressureandtidalvolumeinmL/kg
predictedbodyweight,andtoexplicitlyconsidertheseventilator
variables during bedside rounds, may improve adherence to
lung protective ventilation.
33 36 Finally, only teaching hospitals
were evaluated and exclusion criteria were applied in selecting
eligible patients for this study; hence generalisability of the
findings may be limited. However, four hospitals with 13
intensive care units participated, providing variation in the
medical care provided to participants, and the number of
exclusioncriteriawerelimited(comparedwithrandomisedtrials
of lung protective ventilation) which aids in generalisability.
Conclusion
Lung protective mechanical ventilation is associated with a
substantial survival benefit for patients with acute lung injury
over two year’s follow-up. Average tidal volume showed a
linearrelationwithtwoyearsurvival,suchthatevenarelatively
smalldecreaseinaveragetidalvolumeoverstayintheintensive
care unit was independently associated with an important
decrease in risk of mortality. Given the study’s findings that
patients with acute lung injury often did not receive lung
protective ventilation, greater efforts to implement lung
protective ventilation in routine clinical practice should be
undertaken to reduce patients’ long term mortality.
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RESEARCHTables
Table 1| Patients’ characteristics, by ventilator adherence and mortality status at two years. Values are numbers (percentages) unless
stated otherwise
P value
Mortality status
P value
Ventilator adherence
All patients
(n=485) Characteristics Dead (n=311) Alive (n=174) Ever* (n=303) Never (n=182)
<0.001 56 (47-67) 46 (38-54) 0.002 51 (41-60) 54 (45-69) 53 (42-63) Median (interquartile range) age
(years)
0.703 178 (57) 96 (55) <0.001 197 (65) 77 (42) 274 (57) Males
0.159 22 (7) 5 (3) 0.024 17 (6) 10 (6) 27 (6) Underweight (body mass index <18.5)
100 (32) 50 (29) 106 (35) 44 (24) 150 (31) Normal weight (body mass index
18.5-24.9)
77 (25) 51 (29) 82 (27) 46 (25) 128 (26) Overweight (body mass index 25-30)
112 (36) 68 (39) 98 (32) 82 (45) 180 (37) Obese (body mass index >30)
<0.001 3 (2-5) 1 (0-3) 0.433 2 (1-4) 2 (1-4) 2 (1-4) Median (interquartile range) Charlson
comorbidity index
<0.001 29 (22-36) 22 (18-28) 0.974 27 (21-33) 27 (20-34) 27 (20-33) Median (interquartile range) APACHE
II score
<0.001 113 (36) 30 (17) 0.217 83 (27) 60 (33) 143 (30) Non-pulmonary sepsis as risk factor
for acute lung injury
0.008 274 (88) 137 (79) 0.068 264 (87) 147 (81) 411 (85) Admission to medical intensive care
unit
0.085 121 (39) 82 (47) 0.029 115 (38) 88 (48) 203 (42) Admission to intensive care unit from
emergency department
<0.001 10 (7-14) 5 (4-7) 0.604 8 (5-12) 8 (5-13) 8 (5-12) Median (interquartile range) mean daily
sequential organ failure assessment
score
<0.001 1 (0-6) 3 (1-6) <0.001 3 (0-7) 1 (0-4) 2 (0-6) Median (interquartile range) days of
delirium in intensive care unit
0.951 3 (1-8) 3 (1-7) <0.001 4 (1-9) 2 (1-5) 3 (1-8) Median (interquartile range) days of
deep sedation in intensive care unit
<0.001 229 (74) 96 (55) 0.369 208 (69) 117 (64) 325 (67) Ever received corticosteroids
0.876 6 (3-10) 6 (3-10) 0.683 6 (3-10) 6 (3-11) 6 (3-10) Median (interquartile range) No of days
of corticosteroid use, if any
0.956 346 (161-735) 343 (134-865) 0.262 338 (150-700) 350 (181-863) 346 (156-813) Median (interquartile range) cumulative
dose of prednisone, if any (mg)†
0.659 73 (24) 44 (25) 0.004 86 (28) 31 (17) 117 (24) Ever received neuromuscular blocker
>0.99 1 (1-3) 2 (1-3) 0.583 1 (1-3) 2 (1-3) 2 (1-3) Median (interquartile range) No of days
of neuromuscular blockade, if any
0.978 2 (1-26) 2 (1-19) 0.229 1 (1-21) 2 (1-79) 2 (1-23) Median (interquartile range) cumulative
dose of vecuronium, if any (mg)
<0.001 13 (5-24) 4 (0-11) 0.162 10 (3-22) 8 (3-17) 9 (3-20) Median (interquartile range) cumulative
fluid balance in intensive care unit
(litres)
0.884 36 (12) 21 (12) 0.145 41 (14) 16 (9) 57 (12) High frequency oscillatory ventilation
(ever)
0.011 31 (10) 32 (18) 0.070 46 (15) 17 (9) 63 (13) Airway pressure release ventilation
(ever)
0.982 5 (2-10) 5 (3-9) <0.001 7 (4-12) 3 (2-7) 5 (2-9) Median (interquartile range) days of
ventilation (eligible setting‡)
0.031 8 (5-17) 10 (7-17) <0.001 11 (6-21) 7 (4-13) 9 (5-17) Median (interquartile range) days of
ventilation (all settings)
0.004 13 (6-22) 15 (10-22) <0.001 15 (8-25) 11 (6-18) 13 (8-22) Median (interquartile range) length of
stay in intensive care unit (days)
<0.001 18 (10-34) 24 (17-36) <0.001 24 (15-39) 17 (9-30) 21 (13-36) Median (interquartile range) length of
stay in hospital (days)
APACHE II=acute physiology and chronic health evaluation II.
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RESEARCHTable 1 (continued)
P value
Mortality status
P value
Ventilator adherence
All patients
(n=485) Characteristics Dead (n=311) Alive (n=174) Ever* (n=303) Never (n=182)
*Defined using average of five imputed plateau pressures for patients with missing data.
†Corticosteroid dose presented as prednisone-equivalent dose; conversions done using standard methods.
43
‡Defined as eligible for lung protective ventilation if mechanical ventilation was delivered through an endotracheal or tracheostomy tube with fraction of inspired
oxygen ≥0.50 or positive end expiratory pressure >5 cm of water. Ventilator modes for which tidal volume is not routinely measured (high frequency oscillation or
airway pressure release) were considered not eligible for analysis of lung protective ventilation.
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RESEARCHTable 2| Mechanical ventilation variables by adherence to lung protection and mortality status at two years.* Values are median (interquartile
range) unless stated otherwise
P value‡
Mortality status
P value‡
Ventilator settings†
Ventilation variables Dead (n=4157) Alive (n=2083) Adherent(n=2548)
Non-adherent
(n=3692)
All eligible
(n=6240)
0.971 10 (7-10) 10 (8-10) 0.070 10 (8-10) 10 (5-10) 10 (8-10) Positive end expiratory
pressure (cm H2O)
<0.001 163 (107-208) 188 (128-234) <0.001 165 (113-199) 180 (114-234) 172 (114-215) PaO2:FiO2
<0.001 508 (12) 126 (6) 0.216 255 (10) 379 (10) 634 (10) No (%) with arterial pH
<7.25§
0.177 31 (24-42) 31 (23-42) <0.001 30 (24-39) 32 (23-44) 31 (23-42) Static compliance of
respiratory system
(mL/cm H2O)
0.943 23 (20-27) 23 (20-27) <0.001 23 (20-26) 24 (20-28) 23 (20-27) Plateau pressure¶ (cm
H2O)
0.018 28 (20-35) 26 (20-35) <0.001 30 (24-35) 24 (19-32) 27 (20-35) Respiratory rate
(breaths/min)
0.014 6.6 (5.8-7.8) 6.6 (6.0-7.9) <0.001 5.9 (5.6-6.1) 7.5 (6.8-8.6) 6.6 (5.9-7.8) Tidal volume (mL/kg
predicted body weight)
PaO2=partial pressure of arterial oxygen; FiO2=fraction of inspired oxygen.
*All variables are for eligible mechanical ventilator settings.
†Defined as eligible for lung protective ventilation if mechanical ventilation was delivered through an endotracheal or tracheostomy tube with FiO2 ≥0.50 or positive
end expiratory pressure >5 cm of water. Ventilator modes for which tidal volume is not routinely measured (high frequency oscillation or airway pressure release)
were considered not eligible for analysis of lung protective ventilation.
‡P values are adjusted for within patient correlation using robust variance estimate.
§From arterial blood gas measurements abstracted from medical records twice daily, when available.
¶Plateau pressures represent average value over five imputed datasets for patients with missing values.
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RESEARCHTable 3| Predictors of two year survival for patients with acute lung injury
P value* Adjusted hazard ratio (95% CI) P value* Crude hazard ratio (95% CI) Predictors
0.002 0.97 (0.95 to 0.99) <0.001 1.02 (1.01 to 1.04) No of ventilator settings adherent to lung
protective ventilation
0.182 1.01 (1.00 to 1.02) <0.001 1.02 (1.01 to 1.02) Duration of mechanical ventilation
<0.001 1.03 (1.02 to 1.04) <0.001 1.03 (1.02 to 1.03) Age
0.386 0.89 (0.69 to 1.16) 0.924 1.01 (0.80 to 1.27) Male sex
0.321 1.30 (0.77 to 2.18) 0.103 1.43 (0.92 to 2.23) Underweight (body mass index <18.5)
0.606 0.93 (0.71 to 1.22) 0.274 0.88 (0.70 to 1.11) Overweight or obese (body mass index ≥25)
0.006 1.07 (1.02 to 1.12) <0.001 1.10 (1.06 to 1.15) Charlson comorbidity index
0.647 1.00 (0.98 to 1.01) <0.001 1.05 (1.04 to 1.07) APACHE II score
0.006 1.47 (1.11 to 1.95) <0.001 2.04 (1.61 to 2.58) Non-pulmonary sepsis as risk factor for acute
lung injury
0.131 1.38 (0.90 to 2.11) 0.030 1.46 (1.03 to 2.08) Admission to medical intensive care unit
0.033 0.74 (0.56 to 0.98) 0.091 0.82 (0.65 to 1.04) Admission to intensive care unit from emergency
department
<0.001 1.20 (1.16 to 1.25) <0.001 1.22 (1.18 to 1.25) Mean daily sequential organ failure assessment
score
0.160 1.02 (0.99 to 1.05) <0.001 1.04 (1.03 to 1.06) Days of delirium in intensive care unit
0.508 1.01 (0.98 to 1.04) <0.001 1.04 (1.02 to 1.06) Days of deep sedation in intensive care unit
0.329 1.01 (0.99 to 1.03) <0.001 1.04 (1.03 to 1.04) Days of corticosteroid use
0.984 1.00 (0.99 to 1.01) 0.028 1.01 (1.00 to 1.01) Cumulative dose of prednisone, per 50 mg†
0.036 1.16 (1.01 to 1.33) <0.001 1.16 (1.07 to 1.26) Days of neuromuscular blockade
0.288 1.01 (0.99 to 1.02) 0.119 1.00 (1.00 to 1.01) Cumulative dose of vecuronium, per 5 mg
<0.001 1.02 (1.01 to 1.03) <0.001 1.03 (1.02 to 1.03) Cumulative fluid balance in intensive care unit,
per litre
0.002 0.93 (0.88 to 0.97) 0.022 1.04 (1.00 to 1.07) High frequency oscillatory ventilation, No of
ventilator settings
0.005 0.98 (0.96 to 0.99) 0.689 1.00 (0.99 to 1.02) Airway pressure release ventilation, No of
ventilator settings
<0.001 1.10 (1.05 to 1.16) <0.001 1.12 (1.07 to 1.16) Mean daily positive end expiratory pressure, per
1 cm H2O
0.146 1.00 (1.00 to 1.01) 0.358 1.00 (0.99 to 1.01) Mean daily PaO2:FiO2, per 10 units
0.077 1.04 (0.99 to 1.10) <0.001 1.12 (1.09 to 1.15) No with arterial pH <7.25‡
0.321 0.96 (0.87 to 1.05) 0.421 0.97 (0.90 to 1.05) Mean daily static compliance of respiratory
system, per 10 mL/cm H2O
0.162 1.02 (0.99 to 1.04) <0.001 1.04 (1.03 to 1.06) Mean daily respiratory rate, per 1 breath/min
0.086 1.30 (0.96 to 1.77) 0.033 1.28 (1.01 to 1.60) Second year of study enrolment
0.357 1.17 (0.83 to 1.64) 0.305 0.88 (0.68 to 1.13) Third year of study enrolment
0.133 1.30 (0.92 to 1.84) 0.698 1.05 (0.82 to 1.34) Study site 2
0.257 1.23 (0.85 to 1.77) 0.030 0.76 (0.59 to 0.98) Study site 3 and 4§
APACHE II=acute physiology and chronic health evaluation II; PaO2=partial pressure of arterial oxygen; FiO2=fraction of inspired oxygen.
*From Cox proportional hazards regression model.
†Corticosteroid dose presented as prednisone-equivalent; conversions done using standard methods.
43
‡From arterial blood gas measurements abstracted from medical records twice daily, when available.
§Sites were combined for analysis as site 4 had a small sample size and shared all intensive care unit physicians with site 3.
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RESEARCHFigures
Fig 1 Flow of patients through study
Fig 2 Unadjusted Kaplan-Meier survival curve, with 95% confidence limits, for 485 patients with acute lung injury in primary
analysis
Fig 3 Predicted absolute risk reduction in mortality by adherence to lung protective ventilation. Estimates based on Cox
proportional hazards regression model with time varying covariates used to predict survival estimates for a prototypical
patient with eight eligible mechanical ventilator settings with 0% versus 50% or 0% versus 100% adherence to lung protective
ventilation. The prototypical patient was presumed to survive for at least four days of eligible ventilation and had median
values for all continuous covariates and mode values for binary covariates. Confidence intervals were generated using 500
bootstrap samples
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RESEARCHFig 4 Predicted change in hazard of mortality for increasing mean tidal volume, based on multivariable Cox model, across
485 patients with acute lung injury. A more flexible non-linear Cox model for mean tidal volume (cubic spline with three
degrees of freedom) did not yield significant improvement in model fit compared with linear model (P=0.182 for non-linear
terms in cubic spline model)
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